Boehringer Ingelheim and Zealand Pharma's Nash candidate fast tracked by FDA

Biotech group Zealand Pharma and German partner Boehringer Ingelheim have been given fast track designation by the US FDA for drug candidate BI 456906 meant to treat nonalcoholic steatohepatitis (Nash), Zealand Pharma reveals Wednesday.

Photo: Zealand Pharma / PR

Danish biotechnology firm Zealand Pharma and its German partner, Boehringer Ingelheim, can look forward to expedited case processing time of their drug candidate BI 456906 from the US Food and Drug Administration (FDA) now that the treatment has received fast-track status, informs Zealand Pharma in a statement Wednesday.

With the fast-track status in hand, the two firms face more frequent meetings with the FDA during the process. Similarly, BI 456906 is now a candidate for an accelerated approval process when a possible approval application is submitted to the US medicines authority concerning the relevant drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs